Acorda Therapeutics, Inc. (Nasdaq:
) today announced that Ron Cohen, M.D., Acorda’s President and Chief Executive Officer, will present at the Cowen & Company 33
Annual Health Care Conference on Monday, March 4 at 2:10 pm ET at the Marriott Copley Plaza Hotel in Boston.
A live audio webcast of the presentation can be accessed under “Investor Events” in the Investor section of the Acorda website at
, or you may use the link:
Please log in approximately 5 minutes before the scheduled time of the presentations to ensure a timely connection. Archived versions of this webcast will be available until April 4 on the Investors section of
Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with MS, spinal cord injury and other neurological conditions.
) Extended Release Tablets, 10 mg, in the United States as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an improvement in walking speed. AMPYRA is marketed outside the United States as FAMPYRA
(prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda. AMPYRA and FAMPYRA are manufactured under license from Alkermes Pharma Ireland Limited.
The Company also markets
ZANAFLEX CAPSULES® (tizanidine hydrochloride)
and Zanaflex tablets, a short-acting drug for the management of spasticity. Acorda also receives sales royalties on tizanidine hydrochloride capsules, an authorized generic version of ZANAFLEX CAPSULES, distributed by Actavis, Inc. under its agreement with Acorda.
Acorda has an industry-leading pipeline of novel neurological therapies. The Company is developing Diazepam Nasal Spray for treatment of certain epileptic seizures. It is also studying AMPYRA to improve a range of functional impairments caused by MS, as well as its potential for use in other neurological conditions, including cerebral palsy and post-stroke deficits. In addition, Acorda is developing clinical stage compounds AC105 for acute treatment of spinal cord injury, GGF2 for treatment of heart failure and rHIgM22, a remyelinating monoclonal antibody, for the treatment of MS. GGF2 is also being investigated in preclinical studies as a treatment for neurological conditions such as stroke and spinal cord injury. Chondroitinase, an enzyme that encourages nerve plasticity in spinal cord injury, is in preclinical development.